Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential.
about
Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancerHedgehog signaling pathway: a novel target for cancer therapy: vismodegib, a promising therapeutic option in treatment of basal cell carcinomas.Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.Cholestatic hepatic injury associated with vismodegib, aspirin, and naproxen use: a case study and review of vismodegib safety.Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.
P2860
Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Co-administration of vismodegi ...... ug-drug interaction potential.
@en
Co-administration of vismodegi ...... ug-drug interaction potential.
@nl
type
label
Co-administration of vismodegi ...... ug-drug interaction potential.
@en
Co-administration of vismodegi ...... ug-drug interaction potential.
@nl
prefLabel
Co-administration of vismodegi ...... ug-drug interaction potential.
@en
Co-administration of vismodegi ...... ug-drug interaction potential.
@nl
P2093
P2860
P1476
Co-administration of vismodegi ...... ug-drug interaction potential.
@en
P2093
A Dimitrios Colevas
Dawn Colburn
Jennifer A Low
Monica Mita
Patricia M LoRusso
Richard A Graham
Vikram Malhi
P2860
P2888
P304
P356
10.1007/S00280-012-1996-6
P577
2012-10-11T00:00:00Z
P6179
1037284954